Latar Belakang. Pasien autoimun rentan terhadap infeksi COVID-19 dan luaran yang lebih berat, sehingga penting untuk mendapat vaksinasi. Namun, terdapat kekhawatiran efek samping, kekambuhan penyakit, serta efektivitas dan imunogenitas vaksin. Tujuan. Mengetahui cakupan vaksinasi COVID-19 di Poli Alergi Imunologi RSCM dan faktor-faktor yang berhubungan. Metode. Studi potong lintang ini melibatkan 260 pasien autoimun dari Poli Alergi Imunologi RSCM periode Juli-Agustus 2023. Pengambilan data menggunakan kuesioner. Analisis bivariat dengan Uji Chi-Square atau Fischer dan analisis multivariat dengan regresi Poisson. Hasil. Cakupan vaksinasi COVID-19 pasien autoimun untuk dosis pertama 60%, dosis kedua 57.3%, dan dosis ketiga 40%. Melalui analisis bivariat, didapatkan faktor yang berhubungan dengan cakupan berupa pekerjaan tenaga kesehatan (PR 1,68; p < 0,001), rekomendasi dokter yang merawat (PR 6,47; p<0,001), dan skala persepsi pasien terhadap keparahan penyakit (p<0,001). Analisis multivariat menunjukkan hubungan antara rekomendasi dokter yang merawat (PR 4,67; p<0,001), pekerjaan tenaga kesehatan (PR 1,56; p=0,01), diagnosis SLE (PR 0,81; p=0,003) dan skala persepsi pasien terhadap keparahan penyakit (PR 0,88; p<0,001). Simpulan. Cakupan vaksinasi COVID-19 dosis pertama pada pasien autoimun di Poli Alergi-Imunologi RSCM adalah 60%. Studi ini menemukan hubungan cakupan vaksinasi dengan rekomendasi dokter yang merawat, pekerjaan sebagai tenaga kesehatan, diagnosis SLE, dan persepsi pasien terhadap keparahan penyakit.

---

Background. Autoimmune patients are susceptible to COVID-19 infection and severe outcomes, so it is important to receive vaccination. However, there are concerns about side effects, disease recurrence, and vaccine effectiveness and immunogenicity.

Objective. To explore uptake of COVID-19 vaccination at RSCM Allergy Immunology Clinic and related factors.

Method. This cross-sectional study involved 260 autoimmune patients from the RSCM Allergy Immunology Clinic for July-August 2023. Data was collected with questionnaire. Bivariate analysis with Chi-Square or Fischer Test and multivariate analysis with Poisson regression.

Results. COVID-19 vaccination coverage for autoimmune patients for the first dose is 60%, the second dose is 57.3%, and third dose is 40%. Through bivariate analysis, associated factors were health worker employment (PR 1.68; p < 0.001), recommendation of treating doctor (PR 6.47; p < 0.001), and patients’ perception of their illness (p< 0.001). Multivariate analysis showed association between recommendation of treating doctor (PR 4.67;p<0.001), health worker's occupation (PR 1.56;p=0.01), SLE diagnosis (PR 0.81;p=0.003) and the scale patient perception of disease severity (PR 0.88;p<0.001).

Conclusion. Coverage first dose COVID-19 vaccination in autoimmune patients at RSCM Allergy-Immunology Clinic is 60%. This study found association between recommendation of treating doctor, healthcare workers, SLE diagnosis, and patients’ perception of their illness.